Optimization of PSA screening policies: A comparison of the patient and societal perspectives

Jingyu Zhang, Brian T. Denton, Hari Balasubramanian, Nilay D Shah, Brant A. Inman

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective. To estimate the benefit of PSA-based screening for prostate cancer from the patient and societal perspectives. Method. A partially observable Markov decision process model was used to optimize PSA screening decisions. Age-specific prostate cancer incidence rates and the mortality rates from prostate cancer and competing causes were considered. The model trades off the potential benefit of early detection with the cost of screening and loss of patient quality of life due to screening and treatment. PSA testing and biopsy decisions are made based on the patient's probability of having prostate cancer. Probabilities are inferred based on the patient's complete PSA history using Bayesian updating. Data Sources. The results of all PSA tests and biopsies done in Olmsted County, Minnesota, from 1993 to 2005 (11,872 men and 50,589 PSA test results). Outcome Measures. Patients' perspective: to maximize expected quality-adjusted life years (QALYs); societal perspective: to maximize the expected monetary value based on societal willingness to pay for QALYs and the cost of PSA testing, prostate biopsies, and treatment. Results. From the patient perspective, the optimal policy recommends stopping PSA testing and biopsy at age 76. From the societal perspective, the stopping age is 71. The expected incremental benefit of optimal screening over the traditional guideline of annual PSA screening with threshold 4.0 ng/mL for biopsy is estimated to be 0.165 QALYs per person from the patient perspective and 0.161 QALYs per person from the societal perspective. PSA screening based on traditional guidelines is found to be worse than no screening at all. Conclusions. PSA testing done with traditional guidelines underperforms and therefore underestimates the potential benefit of screening. Optimal screening guidelines differ significantly depending on the perspective of the decision maker.

Original languageEnglish (US)
Pages (from-to)337-349
Number of pages13
JournalMedical Decision Making
Volume32
Issue number2
DOIs
StatePublished - Mar 2012

Fingerprint

Quality-Adjusted Life Years
Prostatic Neoplasms
Biopsy
Guidelines
Costs and Cost Analysis
Markov Chains
Information Storage and Retrieval
Prostate
History
Quality of Life
Outcome Assessment (Health Care)
Mortality
Incidence
Therapeutics

Keywords

  • partially observable Markov decision process
  • patient perspective
  • prostate cancer
  • PSA
  • societal perspective

ASJC Scopus subject areas

  • Health Policy
  • Medicine(all)

Cite this

Optimization of PSA screening policies : A comparison of the patient and societal perspectives. / Zhang, Jingyu; Denton, Brian T.; Balasubramanian, Hari; Shah, Nilay D; Inman, Brant A.

In: Medical Decision Making, Vol. 32, No. 2, 03.2012, p. 337-349.

Research output: Contribution to journalArticle

Zhang, Jingyu ; Denton, Brian T. ; Balasubramanian, Hari ; Shah, Nilay D ; Inman, Brant A. / Optimization of PSA screening policies : A comparison of the patient and societal perspectives. In: Medical Decision Making. 2012 ; Vol. 32, No. 2. pp. 337-349.
@article{130c132bbdb549b8937a389a62ef5029,
title = "Optimization of PSA screening policies: A comparison of the patient and societal perspectives",
abstract = "Objective. To estimate the benefit of PSA-based screening for prostate cancer from the patient and societal perspectives. Method. A partially observable Markov decision process model was used to optimize PSA screening decisions. Age-specific prostate cancer incidence rates and the mortality rates from prostate cancer and competing causes were considered. The model trades off the potential benefit of early detection with the cost of screening and loss of patient quality of life due to screening and treatment. PSA testing and biopsy decisions are made based on the patient's probability of having prostate cancer. Probabilities are inferred based on the patient's complete PSA history using Bayesian updating. Data Sources. The results of all PSA tests and biopsies done in Olmsted County, Minnesota, from 1993 to 2005 (11,872 men and 50,589 PSA test results). Outcome Measures. Patients' perspective: to maximize expected quality-adjusted life years (QALYs); societal perspective: to maximize the expected monetary value based on societal willingness to pay for QALYs and the cost of PSA testing, prostate biopsies, and treatment. Results. From the patient perspective, the optimal policy recommends stopping PSA testing and biopsy at age 76. From the societal perspective, the stopping age is 71. The expected incremental benefit of optimal screening over the traditional guideline of annual PSA screening with threshold 4.0 ng/mL for biopsy is estimated to be 0.165 QALYs per person from the patient perspective and 0.161 QALYs per person from the societal perspective. PSA screening based on traditional guidelines is found to be worse than no screening at all. Conclusions. PSA testing done with traditional guidelines underperforms and therefore underestimates the potential benefit of screening. Optimal screening guidelines differ significantly depending on the perspective of the decision maker.",
keywords = "partially observable Markov decision process, patient perspective, prostate cancer, PSA, societal perspective",
author = "Jingyu Zhang and Denton, {Brian T.} and Hari Balasubramanian and Shah, {Nilay D} and Inman, {Brant A.}",
year = "2012",
month = "3",
doi = "10.1177/0272989X11416513",
language = "English (US)",
volume = "32",
pages = "337--349",
journal = "Medical Decision Making",
issn = "0272-989X",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Optimization of PSA screening policies

T2 - A comparison of the patient and societal perspectives

AU - Zhang, Jingyu

AU - Denton, Brian T.

AU - Balasubramanian, Hari

AU - Shah, Nilay D

AU - Inman, Brant A.

PY - 2012/3

Y1 - 2012/3

N2 - Objective. To estimate the benefit of PSA-based screening for prostate cancer from the patient and societal perspectives. Method. A partially observable Markov decision process model was used to optimize PSA screening decisions. Age-specific prostate cancer incidence rates and the mortality rates from prostate cancer and competing causes were considered. The model trades off the potential benefit of early detection with the cost of screening and loss of patient quality of life due to screening and treatment. PSA testing and biopsy decisions are made based on the patient's probability of having prostate cancer. Probabilities are inferred based on the patient's complete PSA history using Bayesian updating. Data Sources. The results of all PSA tests and biopsies done in Olmsted County, Minnesota, from 1993 to 2005 (11,872 men and 50,589 PSA test results). Outcome Measures. Patients' perspective: to maximize expected quality-adjusted life years (QALYs); societal perspective: to maximize the expected monetary value based on societal willingness to pay for QALYs and the cost of PSA testing, prostate biopsies, and treatment. Results. From the patient perspective, the optimal policy recommends stopping PSA testing and biopsy at age 76. From the societal perspective, the stopping age is 71. The expected incremental benefit of optimal screening over the traditional guideline of annual PSA screening with threshold 4.0 ng/mL for biopsy is estimated to be 0.165 QALYs per person from the patient perspective and 0.161 QALYs per person from the societal perspective. PSA screening based on traditional guidelines is found to be worse than no screening at all. Conclusions. PSA testing done with traditional guidelines underperforms and therefore underestimates the potential benefit of screening. Optimal screening guidelines differ significantly depending on the perspective of the decision maker.

AB - Objective. To estimate the benefit of PSA-based screening for prostate cancer from the patient and societal perspectives. Method. A partially observable Markov decision process model was used to optimize PSA screening decisions. Age-specific prostate cancer incidence rates and the mortality rates from prostate cancer and competing causes were considered. The model trades off the potential benefit of early detection with the cost of screening and loss of patient quality of life due to screening and treatment. PSA testing and biopsy decisions are made based on the patient's probability of having prostate cancer. Probabilities are inferred based on the patient's complete PSA history using Bayesian updating. Data Sources. The results of all PSA tests and biopsies done in Olmsted County, Minnesota, from 1993 to 2005 (11,872 men and 50,589 PSA test results). Outcome Measures. Patients' perspective: to maximize expected quality-adjusted life years (QALYs); societal perspective: to maximize the expected monetary value based on societal willingness to pay for QALYs and the cost of PSA testing, prostate biopsies, and treatment. Results. From the patient perspective, the optimal policy recommends stopping PSA testing and biopsy at age 76. From the societal perspective, the stopping age is 71. The expected incremental benefit of optimal screening over the traditional guideline of annual PSA screening with threshold 4.0 ng/mL for biopsy is estimated to be 0.165 QALYs per person from the patient perspective and 0.161 QALYs per person from the societal perspective. PSA screening based on traditional guidelines is found to be worse than no screening at all. Conclusions. PSA testing done with traditional guidelines underperforms and therefore underestimates the potential benefit of screening. Optimal screening guidelines differ significantly depending on the perspective of the decision maker.

KW - partially observable Markov decision process

KW - patient perspective

KW - prostate cancer

KW - PSA

KW - societal perspective

UR - http://www.scopus.com/inward/record.url?scp=84859304024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859304024&partnerID=8YFLogxK

U2 - 10.1177/0272989X11416513

DO - 10.1177/0272989X11416513

M3 - Article

C2 - 21933990

AN - SCOPUS:84859304024

VL - 32

SP - 337

EP - 349

JO - Medical Decision Making

JF - Medical Decision Making

SN - 0272-989X

IS - 2

ER -